M. Hevey et al., MARBURG VIRUS-VACCINES BASED UPON ALPHAVIRUS REPLICONS PROTECT GUINEA-PIGS AND NONHUMAN-PRIMATES, Virology (New York, N.Y. Print), 251(1), 1998, pp. 28-37
Marburg virus (MBGV), for which no vaccines or treatments currently ex
ist, causes an acute hemorrhagic fever with a high mortality rate in h
umans. We previously showed that immunization with either killed MBGV
or a glycoprotein (GP) subunit prevented lethal infection in guinea pi
gs. In the studies reported here, an RNA replicon, based upon Venezuel
an equine encephalitis (VEE) virus, was used as a vaccine vector; the
VEE structural genes were replaced by genes for MBGV GP, nucleoprotein
(NP), VP40, VP35, VP30, or VP24. Guinea pigs were vaccinated with rec
ombinant VEE replicons (packaged into VEE-like particles), inoculated
with MBGV, and evaluated for viremia and survival. Results indicated t
hat either GP or NP were protective antigens while VP35 afforded incom
plete protection. As a more definitive test of vaccine efficacy, nonhu
man primates (cynomolgus macaques) were inoculated with VEE replicons
expressing MBGV GP and/or NP. Three monkeys received packaged control
replicons (influenza HA); these died 9 or 10 days after challenge, wit
h typical MBGV disease. MBGV NP afforded incomplete protection, suffic
ient to prevent death but not disease in two of three macaques. Three
monkeys Vaccinated with replicons which expressed MBGV GP, and three o
thers vaccinated with both replicons that expressed GP or NP, remained
aviremic and were completely protected from disease.